11 NCEs added to Japan's NHI drugprice lis, inc Erbitux, Macugen and Nazonex
Among the 11 New Chemical Entities/16 products to be added to Japan's National Health Insurance drug price list on September 13, were German drugmaker Merck Serono's Erbitux (cetuximab) for colorectal cancer, global pharmaceutical giant Pfizer's Macugen (pegatanib sodium) for age-related macular degeneration, and US drug major Schering-Plough's Nasonex (mometasone furoate hydrate).
The price of Erbitux Injection 100mg capsule for the treatment of inoperable advanced and recurrent colorectal cancer, was set at 35,894 yen ($330.22) with a 19.2% premium of an average operating profit ratio. Turnover of the drug is expected to reach 2.15 billion yen in the first year on the market and 8.58 billion yen at peak in the fourth year.
Hefty premiums for Macugen
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze